Zusammenfassung
Da tier- und humanexperimentell ermittelte pharmakologische und biochemische Untersuchungsergebnisse lediglich Aussagen zur Wirkung der Nootropika zulassen, muß die Bewertung der Wirksamkeit ausschließlich nach klinischen Kriterien erfolgen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
American Psychiatric Association (1989) Diagnostisches und statistisches Manual psychischer Störungen DSM-III-R. Übersetzt nach der Revision des Diagnostic and Statistical Manual of Mental Disorders der American Psychiatric Association. Deutsche Bearbeitung und Einführung von Wittchen H-U, Sass H, Zaudig M, Koehler K. Beltz, Weinheim
Bergener M, Reisberg B (eds) (1989) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo
Brunner C, Spiegel R (1990) Eine Validierungsstudie mit der Nosger (Nurses’ Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie. Z Klin Psychol 19: 1–19
Buschke H (1973) Selective reminding for analysis of memory and learning. J Verbal Learning verbal Behav 12: 543–550
Carlsson A (1987) Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology 33: 159–167
Ciompi L, Kanowski S et al. (1986) Dokumentationssystem der Arbeitsgemeinschaft für Gerontopsychiatrie. In: Collegium Internationale Psychiatriae Scalarum (Hrsg) Internationale Skalen für Psychiatrie. Beltz, Weinheim
Cips Collegium Internationale Psychiatriae Scalarium (Hrsg) (1986) Internationale Skalen für Psychiatrie. Beltz, Weinheim
Clinical Global Impressions (CGI) (1970) In: Guy W, Bonato RR (eds) Manual for the ECDEU assessment battery, 2nd revised ed. Chevy Chase, Maryland 1: 12–1–12–6
Copeland JRM, Kelleher MJ, Kellett JM, Gourlay AJ, Gurland BJ, Fleiss JL, Sharp L (1976) A semistructured clinical interview for assessment of diagnosis and mental state in the elderly. The geriatric mental state schedule. I. Development and reliability. Psychol Med 6: 439–449
Copeiand JRM, Mcwilliam C, Dewey ME, Forshaw D, Shiwach R, Abed R, Muthu MS, Wood N (1986) The early recognition of dementia in the elderly: a preliminary communication about a longitudinal study using the Gmsagecat package (community version). Int J Geriatr Psychol 1: 63–70
Coper H, Herrmann WM (1988) Psychostimulants, analgetics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217
Das Amdp-System (1981) Manual zur Dokumentation psychiatrischer Befunde, 4. Aufl. Springer, Berlin Heidelberg New York
Crook T, Larrabee GJ (1988) Age-associated memory impairment. Diagnostic and therapeutic strategies. Psychopharmacol Bull 24: 509–514
Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsnachweis “Demenz” (Phase III) (1991) Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission für neue Stoffe (Kornmission A) und der Aufbereitungskommission “Neurologie, Psychiatrie” (Kommission B). Bunclesgesundheitsblatt 7: 342–350
Erzigkeit H (1986) Syndrom-Kurz-Test, 2. überarbeitete Aufl. Vless, Ebersberg
Ferris SH, Crook T, Clark E, Mccarthy M, Rae D (1980) Facial recognition memory deficits in normal aging and senile dementia. J Gerontol 35: 707–714
Fletcher JC, Dommel FW JR, Cowell DD (1985) Consent to research with impaired human subjects. IRB. Rev. Hum Subject Res 7: 1–6
Folstein MF, Folstein SE, Mchugh PR (1975) MiniMental-State. A practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 12: 189–198
Fröstl W, Maître L (1989) The families of cognition enhancers. Pharmacopsychiatry 22: 54– 100
Giotti A (ed) (1986) Drugs affecting cognitive disorders. Clin Neuropharmacol 9 [Suppl] 1–84
Gottfries CG, Braine G, Steen G (1982) A new rating scale for dementia syndromes. Gerontology 28 [Suppl 2]: 20–31
Giurgea CE (1972) Vers une pharmacologie de l’activitè integrative au cerveau. Tentative du concept nootrope en psychopharmacologie. Actual Pharmacol 25: 115–157
Giurgea CE (1979) Nootropic and related drugs interacting with the integrative activity of the brain. Dev Psychiatry 2: 876–881
Giurgea CE (1982) The nootropic concept and its prospective implications. Drug Dev Res 2: 441–446
Gutzmann H, Kanowski S, Krüger H, Urban R, Ciompi L (1989) Das AGP-System. Manual zur Dokumentation gerontopsychiatrischer Befunde. Springer, Berlin Heidelberg New York Tokyo
Häfner H (1986) Psychische Gesundheit im Alter. G Fischer, Stuttgart New York
Heiss WD, Beil C, Herholz K, Pawlik G, Wagner R, Wienhard K (1983) Atlas der Positronen-Emissions-Tomographie des Gehirns. Springer, Berlin Heidelberg New York Tokyo
Helmchen H (1986) Ethische Fragen der Psychiatrie. In: Kisker KP, Lauter H, MEYER JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart, Bd 2. Krisenintervention, Suizid. Konsiliarpsychiatrie. Springer, Berlin Heidelberg New York Tokyo
Helmchen H, Kanowski S, Koch H-G (1989) Forschung mit dementen Kranken. Forschungsbedarf und Einwilligungsproblematik. Ethik in der Medizin 1: 83–98
Helmes E (1988) Multidimensional observation scale elderly subjects (MOSES). Psychopharmacol Bull 24: 733–745
Hock FJ (1987) Drug influence on learning and memory in aged animals and humans. Neuropsychobiology 17: 145–160
Kam P Van Der, Mol F, Wimmers MFHG (1971) Beoordelingsschool voor Oudere Patienten. Van Loghum Slaterus, Niederlande
Keim KL, Kiss B (eds) New drug strategies in the treatment of senile dementia of different origin. Drug Dev Res 14: 181–384
Larrabee GJ, Crook T (1988) A computerized everyday memory battery for assessing treatment effects. Psychopharmacol Bull 24: 695–697
Lauter H, Möller HJ, Zimmer R (1986) Untersuchungs- und Behandlungsverfahren in der Gerontopsychiatrie. Springer, Berlin Heidelberg New York Tokyo
Lawton MG, Brody EM (1969) Assessment of older people. Self-maintaining an instrumental activities of daily living. Gerontologist 9: 179–186
Lehmann E (1984) Practicabel and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsychiatry 17: 71–75
Levine RL (1986) Ethics and regulation of clinical research. Urban & Schwarzenberg, Baltimore München
Lynch G, Larson J, Staubli U, Baudry M (1987) New perspectives on the physiology, chemistry and pharmacology of memory. Drug Dev Res 10: 295–315
Markstein R (1989) Pharmacological approaches in the treatment of senile dementia. Eur Neurol 28: 136–144
Matthies H (1985) Zentralnervensystem. In: Markwardt F, Matthies H, Oelssner W (Hrsg) Medizinische Pharmakologie. VEB Georg Thieme, Leipzig
Maurer K, Riederer P, Beckmann H (eds) (1990) Alzheimer’s disease. Epidemiology, neuropathology, neurochemistry and clinics. Springer, Wien New York (Key topics in brain research)
Merlini L, Pinza M (1989) Trends in searching for new cognition enhancing drugs. Prog NeuroPsychopharmacol Biol Psychiatry 13: 61–75
Mohs RC, Rosen WG, Davis KL (1983) The Alzheimer’s disease asssessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 19: 448–449
Moos WH, Davis E, Schwarz RD, Gamzu ER (1988) Cognition activators. Med Res Rev 8: 353–391
Oswald WD, Fleischmann UM (1986) Das Nürnberger-Alters-Inventar NAI. Hogrefe, Göttingen
Oswald WD, Roth E (1987) Der Zahlen-Verbindungs-Test, 2. Aufl. Hogrefe, Göttingen
Oswald WD, Fleischmann UM (1989) Psychometric assessment in psychogeriatrics. In: Bergener M et al. (eds) Psychogeriatrics — A new paradigm on basic research and clinical practice. Springer, New York
Pfeiffer E (1975) Short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23: 433–441
Reisberg B, Ferris SH, DE Leon MJ, Crook T (1982) The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry 139: 1136–1139
Reisberg B, Schneck MK, Ferris SH, Schwarz GE, DE Leon MJ (1983) The brief cognitive rating scale (BCRS). Psychopharmacol Bull 19: 47–50
Reitan RM (1985) Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills 8: 271–276
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1364
Rom M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) Camdex — A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698–709
Schindler U (1989) Pre-clinical evaluation of cognition enhancing drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 13: 99–115
Schmidt J (1984) Zur Pharmakologie der Nootropika. Beiträge zur Wirkstofforschung Heft 17. Akademie-Industrie-Komplex-Arzneimittelforschung, Berlin
Schneider HD, Fisch HP (1981) Der geriatrische Beurteilungsbogen (GBB): Ein Instrument zur Einschätzung des Alltagsverhaltens geriatrischer Patienten durch das Pflegepersonal. In: Oswald WD, Fleischmann UM (Hrsg) Experimentelle Gerontopsychologie. Beltz, Weinheim, S 116–130
Schwartz GE (1983) Development and validation of the geriatic evaluation by the relative’s rating instrument (GERRJ). Psychol Reports 53: 479–488
Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessment in geriatric populations: Sandoz clinical assessment geriatric scale (SCAG). J Am Geriatr Soc 22: 107–113
Skondia V (1979) Criteria for clinical development and classification of nootropic drugs. Clin Ther 2/5: 316–332
Thomae H (1984) Lebenszufriedenheit. In: Oswald WD, Hermann WM, Kanowski S, LEHR UM, Thomae H (Hrsg) Gerontologie. Kohlhammer, Stuttgart, S 271–275
Wechsler D (1964) Die Messung der Intelligenz Erwachsener. Hogrefe, Göttingen
Wenk GL, Olton DS (1989) Cognitive enhancers: potential strategies and experimental results. Prog Neuro-Psychopharmacol Biol Psychiatry 13: 117–139
Wood WG, Strong R (eds) (1987) Geriatric clinical pharmacology. Raven Press, New York
Wurtman RJ, Corkin S, Growdon HJ (eds) (1987) Topics in the basic and clinical science of dementia. J Neural Transm [Suppl 24]: 1–329
Who (1989) Draft of the intemational classification of disease, 10th revision (ICD 10). Genova
Zaudig M, Mittelhammer J, Hiller W, Pauls A, Thora C, Morinigo A, Mombour W (1991) SIDAM-A structured interview for the diagnosis of dementia of the Alzheimer type, multiinfarct dementia and dementias of other aetiology according to ICD 10 and DSM III-R. Psychol Med 21: 225–236
Zimmer R, Kurz A, Lauter H (1987) Zur klinischen Relevanz nootroper Effekte. In: Cooper H, Heimann H, Kanowski S, Kunkel H (Hrsg) Hirnorganische Psychosyndrome im Alter III. Springer, Berlin Heidelberg New York Tokyo, S 54–61
Alhainen K, Riekkinen PJ, Helkala EL, Partanen Laulumaa V, Reinikainen K, Soininen H, Airaksinen M (1991) The effects of THA on cognitive functions and spectral power EEG in Alzheimer’s disease: preliminary results of an open study. In: IQBAL K, Mclachlan DRC, Winblad B, Wisniewski HM (eds) Alzheimer’s disease: basis mechanism, diagnosis and therapeutic strategies. Wiley, Chichester New York, pp 611–619
Amaducci L, Angst J, Bech P, Benkert O, Bruinvels J, Engel RR, Gottfries CG, Hippius H, Levy R (1990) Consensus conference on the methodology of clinical trials of “Nootropics”. Pharmacopsychiatry 23: 171–175
American Electroencephalographic Society (1987) Statement on the clinical use of quantitative EEG. J Clin Neurophysiol 4: 197
Coper H, Herrmann WM (1988) Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217
Dierks T, Maurer K (1990) Reference-free evaluation of auditory evoked potentials P300 in aging and dementia. In: Dostert P, Riederer P, Strolin Benedetti M, Roncucci R (eds) Early markers in Parkinson’s and Alzheimer’s disease. Springer, Wien New York, pp 197–208 (New Vistas in Drug Research)
Dierks T, Perisic I, Froelich L, IHL R, Maurer K (1991) Topography of quantitative EEG in dementia of Alzheimer type: relation to severity of dementia. Psychiatry Res 40: 181–194
Dietrich B, Herrmann WM, Coppola R (1989) Untersuchungen zur Wirkung von Phosphatidylserine-Fidia auf eine funktionale zerebrale Ebene mit Hilfe der EEG-Mapping-Technik. In: Saletu B (Hrsg) Biologische Psychiatrie. Thieme, Stuttgart New York, S 238–240
Duffy FH, Burchfiel JL, Lombroso CT (1979) Brain electrical activity mapping (BEAM): a method for extending the clinical utility of EEG and evoked potential data. Ann Neurol 5: 309–321
Duffy FH, Albert MS, Mcanulty G (1984) Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 16: 439–448
Dummermuth G, Ferber G, Herrmann WM, Hinrichs H, Kuenkel H (1987) Recommendations for standardization of data acquisition and signal analysis in pharmaco-electroencephalography. Neuropsychobiology 17: 213–218
Fink M (1969) EEG and human psychopharmacology. A Rev Pharmacol 9: 241–258
Fink M (1975) Central electrometry-quantitative EEG applied to human psychopharmacology. In: Dolce G, Kunkel H (eds) CEAN-computerized EEG-analysis. Fischer, Stuttgart
Fritze J, Dierks T, Maurer K (1989) EEG mapping during cholinergic drug challenge with RS-86. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York Tokyo, pp 518–521
Fünfgeld EW (1989) A natural and broad spectmm nootropic substance for treatment of SDAT — the ginkgo biloba extract. Prog Clin Biol Res 317: 1247–1260
Grossmann WM, Standl A, May U, Van Laak HH, Hirche H (1990) Naftidrofuryl in the treatment of mild senile dementia. Pharmacopsychiatry 23: 265–273
Herrmann WM (1982a) Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In: Herrmann WM (ed) Electroencephalography in drug research. Fischer, Stuttgart, pp 249–351
Herrmann WM (1982b) Electroencephalography and drug research. Fischer, Stuttgart
Herrmann WM, Scharer E (1988) Wirkungen und Wirksamkeit von Nootropika. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 71–93
Herrmann WM, Kern U, Roehmel J (1986) Contribution to the search of vigilance indicative EEG variables: results of a controlled, doubleblind study with pyritinol in elderly patients with symptoms of mental dysfunction. Pharmacopsychiatry 19: 75–83
Herrmann WM, Coppola R, Etevenon P, Ferber G, Fink M, Gevins AS, Hinrichs H, Itil TM, John ER, Kubicki ST, Kuenkel H, Kugler J, Lehmann D, Petsche H, Rappelsberger P, Roehmel J, Saito M, Saletu B, Scheuler W (1989a) International Pharmaco-EEG Group (IPEG). Recommendations for EEG and evoked potential mapping. Neuropsychobiology 22: 170–176
Herrmann WM, Kubicki ST, Kuenkel H, Kugler J, Lehmann D, Maurer K, Rappelsberger P, Scheuler W (1989b) Empfehlungen der Deutschen EEG-Gesellschaft für das Mapping von EEG-Parametern (EEG- und EP- Mapping). EEG-EMG 20: 125–132
Ihl R, Dierks T, Maurer K (1989a) Demenz vom vaskulärem Typ — Effekte einer Infusionstherapie mit Xantinolnicotinat. In: Saletu B (Hrsg) Biologische Psychiatrie. Thieme, Stuttgart New York, S 232–234
Ihl R, Frölich L, Dierks T, Maurer K (1989b) Influence of physostigmine on cognitive processing of the brain. In: Basar E et al. (eds) Springer Series in Brain Dynamics 2. Springer, Berlin Heidelberg New York Tokyo, pp 429–435
Ihl R, Maurer K, Dierks T, Wannenmacher W (1989c) EEG and EP mapping in patients with senile dementia of Alzheimer type before and after treatment with pyritinol. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York Tokyo, pp 241–248
Itil TM (1974) Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: ITIL TM (ed) Psychotropic drugs and the human EEG. Karger, Basel, pp 43–75
Itil TM, Menon GN, Songar A, Itil KZ (1986) CNS pharmacology and clinical therapeutic effects of oxiracetam. Clin Neuropharmacol 9 [Suppl 3]: S70–S72
Kraaier V, Van Huffelen AC, Wieneke GH (1989) The hyperventilation-induced ischaemia model in human neuropharmacology: neurophysiological and psychometric studies of aniracetam and 3-OH aniracetam. Eur J Clin Pharmacol 36: 605–611
Krassner MB (1984) Mechanism of action of hydergin (ergoloid mesylates) in relation to organic brain disorders. Adv Ther 1: 172–188
Lehmann D (1971) Multichannel topography of human alpha EEG fields. Electroencephalogr Clin Neurophysiol 31: 439–449
Leponcin-Lafitte M (1985) Learning and cholinergic neurotransmission in old animals: the effect of hydergine. J Pharmacol 16: 57–63
Maurer K, Dierks T (1991) Atlas of brain mapping. Springer, Berlin Heidelberg New York Tokyo
Maurer K, Dierks T, Ihl R (1989a) The effect of pyritinol upon P300 topography. Psychiatry Res 29: 413–415
Maurer K, Riederer P, Heinsen H, Beckmann H (1989b) Altered P300 topography due to functional and structural disturbances in the limbic system in dementia and psychoses and to psychopharmacological conditions. Psychiatry Res 29: 391–394
Maurer K, Dierks T, Strik WK, Frölich L (1990) P3 topography in psychiatry and psychopharmacology. Brain Topogr 3: 79–84
Münte TT, Heinze HJ, Scholz MB, Bartusch SM, Dietrich De (1989) Event-related potentials and visual spatial attention: influence of a cholinergic drug. Neuropsychobiology 21: 94–99
Pfefferbaum A, Wenegrat BG, Ford JM, Roth WT, Kopell BS (1984) Clinical application of the P3 component of event-related potentials. II. Dementia, depression and schizophrenia. Electroencephalogr Clin Neurophysiol 59: 104–124
Rupprecht R, Maurer K, Dierks T, Ihl R (1989) Topographic mapping of pharmaco-EEG before and after application of phosphatidylserine. Psychiatry Res 29: 417–418
Saletu B, Linzmayer L, Grünberger J, Pietschmann H (1985) Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life. Neuropsychobiology 13: 44–52
Saletu B, Anderer P, Kinsberger K, Grünberger J (1987) Topographic brain mapping of EEG in neuropsychopharmacology. Part II. Clinical applications (pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 9: 385–408
Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhof PK, Litschauer G, Wagner G, Hatzinger R, Dittrich R (1988) EEG brain mapping in SDAT and MID patients before and during placebo and xantinolnicotinate therapy: reference considerations. In: Samsondolfuss (ed) Statistics and topography in quantitative EEG. Elsevier, Paris, pp 251–275
Saletu B, Anderer P, Kinsberger K, Grünberger J (1989a) Topographic EEG brain maps and mental performance under hypoxia after placebo and pyritinol. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York, pp 527–534
Saletu B, Darragh A, Salmon P, Coen R (1989b) EEG brain mapping in evaluating the timecourse of the central action of DUP 996 — a new acetylcholine releasing drug. Br J Clin Pharmacol 28: 1–16
Saletu B, Semlitsch HV, Anderer P, Resch F, Presslich O, Schuster P (1989c) Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese psychophysiological test-system (VPTS). Meth Find Exp Clin Pharmacol 11: 43–55
Saletu B, Anderer P, Grünberger J (1990a) Topographic mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 11: 1–22
Saletu B, Grünberger J, Anderer P (1990b) On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 28: 510–524
Saletu B, Grünberger J, Linzmayer L, Anderer P (1990c) Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm [PD-Sect] 2: 305–325
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Wien
About this chapter
Cite this chapter
Herrschaft, H., Dierks, T., Ihl, R., Maurer, K. (1992). Klinische Bewertung der Wirksamkeit von Nootropika. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3330-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3330-9_11
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3331-6
Online ISBN: 978-3-7091-3330-9
eBook Packages: Springer Book Archive